Browse LEF1

Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Found in nuclear bodies upon PIASG binding.
Domain PF08347 N-terminal CTNNB1 binding
PF00505 HMG (high mobility group) box
Function

Participates in the Wnt signaling pathway. Activates transcription of target genes in the presence of CTNNB1 and EP300. May play a role in hair cell differentiation and follicle morphogenesis. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1. Regulates T-cell receptor alpha enhancer function. Binds DNA in a sequence-specific manner. PIAG antagonizes both Wnt-dependent and Wnt-independent activation by LEF1 (By similarity). Isoform 3 lacks the CTNNB1 interaction domain and may be an antagonist for Wnt signaling. Isoform 5 transcriptionally activates the fibronectin promoter, binds to and represses transcription from the E-cadherin promoter in a CTNNB1-independent manner, and is involved in reducing cellular aggregation and increasing cell migration of pancreatic cancer cells. Isoform 1 transcriptionally activates MYC and CCND1 expression and enhances proliferation of pancreatic tumor cells.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001525 angiogenesis
GO:0001558 regulation of cell growth
GO:0001569 patterning of blood vessels
GO:0001649 osteoblast differentiation
GO:0001667 ameboidal-type cell migration
GO:0001701 in utero embryonic development
GO:0001704 formation of primary germ layer
GO:0001707 mesoderm formation
GO:0001755 neural crest cell migration
GO:0001756 somitogenesis
GO:0001763 morphogenesis of a branching structure
GO:0001818 negative regulation of cytokine production
GO:0001837 epithelial to mesenchymal transition
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0002040 sprouting angiogenesis
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002200 somatic diversification of immune receptors
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002568 somatic diversification of T cell receptor genes
GO:0002573 myeloid leukocyte differentiation
GO:0002681 somatic recombination of T cell receptor gene segments
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0003002 regionalization
GO:0006310 DNA recombination
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0007159 leukocyte cell-cell adhesion
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007223 Wnt signaling pathway, calcium modulating pathway
GO:0007369 gastrulation
GO:0007389 pattern specification process
GO:0007405 neuroblast proliferation
GO:0007423 sensory organ development
GO:0007498 mesoderm development
GO:0007517 muscle organ development
GO:0009755 hormone-mediated signaling pathway
GO:0009952 anterior/posterior pattern specification
GO:0010001 glial cell differentiation
GO:0010171 body morphogenesis
GO:0010466 negative regulation of peptidase activity
GO:0010717 regulation of epithelial to mesenchymal transition
GO:0010718 positive regulation of epithelial to mesenchymal transition
GO:0010951 negative regulation of endopeptidase activity
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0014706 striated muscle tissue development
GO:0016049 cell growth
GO:0016055 Wnt signaling pathway
GO:0016202 regulation of striated muscle tissue development
GO:0016444 somatic cell DNA recombination
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0017145 stem cell division
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0021535 cell migration in hindbrain
GO:0021536 diencephalon development
GO:0021537 telencephalon development
GO:0021542 dentate gyrus development
GO:0021543 pallium development
GO:0021761 limbic system development
GO:0021766 hippocampus development
GO:0021854 hypothalamus development
GO:0021861 forebrain radial glial cell differentiation
GO:0021872 forebrain generation of neurons
GO:0021873 forebrain neuroblast division
GO:0021879 forebrain neuron differentiation
GO:0021932 hindbrain radial glia guided cell migration
GO:0021943 formation of radial glial scaffolds
GO:0021953 central nervous system neuron differentiation
GO:0022407 regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030217 T cell differentiation
GO:0030223 neutrophil differentiation
GO:0030307 positive regulation of cell growth
GO:0030326 embryonic limb morphogenesis
GO:0030335 positive regulation of cell migration
GO:0030509 BMP signaling pathway
GO:0030851 granulocyte differentiation
GO:0030852 regulation of granulocyte differentiation
GO:0030854 positive regulation of granulocyte differentiation
GO:0030879 mammary gland development
GO:0030900 forebrain development
GO:0030902 hindbrain development
GO:0032091 negative regulation of protein binding
GO:0032616 interleukin-13 production
GO:0032633 interleukin-4 production
GO:0032634 interleukin-5 production
GO:0032656 regulation of interleukin-13 production
GO:0032673 regulation of interleukin-4 production
GO:0032674 regulation of interleukin-5 production
GO:0032696 negative regulation of interleukin-13 production
GO:0032713 negative regulation of interleukin-4 production
GO:0032714 negative regulation of interleukin-5 production
GO:0032943 mononuclear cell proliferation
GO:0033151 V(D)J recombination
GO:0033153 T cell receptor V(D)J recombination
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035239 tube morphogenesis
GO:0035282 segmentation
GO:0035567 non-canonical Wnt signaling pathway
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035821 modification of morphology or physiology of other organism
GO:0036445 neuronal stem cell division
GO:0040017 positive regulation of locomotion
GO:0042063 gliogenesis
GO:0042088 T-helper 1 type immune response
GO:0042093 T-helper cell differentiation
GO:0042100 B cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042475 odontogenesis of dentin-containing tooth
GO:0042476 odontogenesis
GO:0042692 muscle cell differentiation
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043392 negative regulation of DNA binding
GO:0043393 regulation of protein binding
GO:0043401 steroid hormone mediated signaling pathway
GO:0043473 pigmentation
GO:0043543 protein acylation
GO:0043586 tongue development
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0043921 modulation by host of viral transcription
GO:0043923 positive regulation by host of viral transcription
GO:0043966 histone H3 acetylation
GO:0043967 histone H4 acetylation
GO:0044033 multi-organism metabolic process
GO:0045063 T-helper 1 cell differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045843 negative regulation of striated muscle tissue development
GO:0045861 negative regulation of proteolysis
GO:0045927 positive regulation of growth
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046651 lymphocyte proliferation
GO:0046782 regulation of viral transcription
GO:0048066 developmental pigmentation
GO:0048069 eye pigmentation
GO:0048103 somatic stem cell division
GO:0048332 mesoderm morphogenesis
GO:0048339 paraxial mesoderm development
GO:0048340 paraxial mesoderm morphogenesis
GO:0048341 paraxial mesoderm formation
GO:0048514 blood vessel morphogenesis
GO:0048524 positive regulation of viral process
GO:0048545 response to steroid hormone
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048634 regulation of muscle organ development
GO:0048635 negative regulation of muscle organ development
GO:0048732 gland development
GO:0048736 appendage development
GO:0048747 muscle fiber development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048762 mesenchymal cell differentiation
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0050434 positive regulation of viral transcription
GO:0050792 regulation of viral process
GO:0050909 sensory perception of taste
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051101 regulation of DNA binding
GO:0051146 striated muscle cell differentiation
GO:0051272 positive regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0052312 modulation of transcription in other organism involved in symbiotic interaction
GO:0052472 modulation by host of symbiont transcription
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0055057 neuroblast division
GO:0060019 radial glial cell differentiation
GO:0060021 palate development
GO:0060033 anatomical structure regression
GO:0060070 canonical Wnt signaling pathway
GO:0060173 limb development
GO:0060323 head morphogenesis
GO:0060324 face development
GO:0060325 face morphogenesis
GO:0060326 cell chemotaxis
GO:0060438 trachea development
GO:0060485 mesenchyme development
GO:0060537 muscle tissue development
GO:0060541 respiratory system development
GO:0060561 apoptotic process involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060563 neuroepithelial cell differentiation
GO:0060669 embryonic placenta morphogenesis
GO:0060710 chorio-allantoic fusion
GO:0060711 labyrinthine layer development
GO:0060713 labyrinthine layer morphogenesis
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061053 somite development
GO:0061138 morphogenesis of a branching epithelium
GO:0061152 trachea submucosa development
GO:0061153 trachea gland development
GO:0061351 neural precursor cell proliferation
GO:0061458 reproductive system development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070670 response to interleukin-4
GO:0071353 cellular response to interleukin-4
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071593 lymphocyte aggregation
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0071838 cell proliferation in bone marrow
GO:0071839 apoptotic process in bone marrow
GO:0071863 regulation of cell proliferation in bone marrow
GO:0071864 positive regulation of cell proliferation in bone marrow
GO:0071865 regulation of apoptotic process in bone marrow
GO:0071866 negative regulation of apoptotic process in bone marrow
GO:0071895 odontoblast differentiation
GO:0071898 regulation of estrogen receptor binding
GO:0071899 negative regulation of estrogen receptor binding
GO:0072089 stem cell proliferation
GO:0072132 mesenchyme morphogenesis
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0198738 cell-cell signaling by wnt
GO:1900120 regulation of receptor binding
GO:1900121 negative regulation of receptor binding
GO:1901861 regulation of muscle tissue development
GO:1901862 negative regulation of muscle tissue development
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902262 apoptotic process involved in patterning of blood vessels
GO:1902742 apoptotic process involved in development
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
GO:1904837 beta-catenin-TCF complex assembly
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
GO:2000147 positive regulation of cell motility
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0003707 steroid hormone receptor activity
GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004869 cysteine-type endopeptidase inhibitor activity
GO:0008013 beta-catenin binding
GO:0008134 transcription factor binding
GO:0008301 DNA binding, bending
GO:0030284 estrogen receptor activity
GO:0030331 estrogen receptor binding
GO:0030414 peptidase inhibitor activity
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0035326 enhancer binding
GO:0042393 histone binding
GO:0042826 histone deacetylase binding
GO:0043027 cysteine-type endopeptidase inhibitor activity involved in apoptotic process
GO:0043028 cysteine-type endopeptidase regulator activity involved in apoptotic process
GO:0045295 gamma-catenin binding
GO:0051427 hormone receptor binding
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
GO:0070016 armadillo repeat domain binding
GO:0070742 C2H2 zinc finger domain binding
Cellular Component GO:0005667 transcription factor complex
GO:0032993 protein-DNA complex
GO:0044798 nuclear transcription factor complex
GO:0090575 RNA polymerase II transcription factor complex
GO:1990907 beta-catenin-TCF complex
> KEGG and Reactome Pathway
 
KEGG hsa04310 Wnt signaling pathway
hsa04390 Hippo signaling pathway
hsa04520 Adherens junction
hsa04916 Melanogenesis
Reactome R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-4411364: Binding of TCF/LEF
R-HSA-4086398: Ca2+ pathway
R-HSA-3769402: Deactivation of the beta-catenin transactivating complex
R-HSA-195253: Degradation of beta-catenin by the destruction complex
R-HSA-201722: Formation of the beta-catenin
R-HSA-4641265: Repression of WNT target genes
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LEF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LEF1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29866045Lung AdenocarcinomaInhibit immunityMoreover, the LEF1/MSC module was specifically activated in LUAD and likely to confer epithelial-to-mesenchymal transition, known important for cancer malignant progression and metastasis.
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LEF1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LEF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0970.865
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0730.973
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2240.888
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2180.554
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.410.767
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.020.992
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0960.876
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.390.822
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0010.999
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.1720.0437
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.4260.19
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.30.0443
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LEF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LEF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LEF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LEF1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LEF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LEF1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LEF1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLEF1
Namelymphoid enhancer-binding factor 1
Aliases TCF1ALPHA; TCF10; TCF7L3; LEF-1; T cell-specific transcription factor 1-alpha; TCF1-alpha
Chromosomal Location4q23-q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LEF1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LEF1.
ID Name Drug Type Targets #Targets
DB00903Etacrynic acidSmall MoleculeATP1A1, GSTP1, LEF1, SLC12A14